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ABSTRACT  
Estrogen receptor (ER) binds to DNA indirectly through other transcription factors (e.g. AP-1) 
to modulate gene expression, which is a tethering mechanism. The ER/AP-1 crosstalk plays 
an important role in tamoxifen therapy resistance. However, the overlap in DNA binding 
profiles of ER and AP-1 transcription factors at genome-wide level has not been described. 
Moreover, AP-1 plays a pivotal role in various cellular processes in breast cancer. The 
transcriptional activity of AP-1 is controlled by coregulators, thereby regulating the 
expression of specific genes. Understanding protein-protein interactions is fundamental to the 
mechanism of AP-1 signaling. In addition, ERα is one of the key biomarkers for diagnosis 
and endocrine therapy of breast cancer. However, ERα status is not considered to be a perfect 
marker for responsiveness to anti-estrogens. It has been shown that ERβ may act as a tumor 
suppressor and could be a therapeutic target for breast cancer, however the functions of ERβ 
in this setting remain to be further explored. The use of multi-functional genomic 
technologies to identify cistrome, transcriptome and proteome of ER or AP-1 has resulted in 
comprehensive deciphering of the role of the ER and AP-1 in breast cancer, which also 
provides information for developing novel therapeutic strategies for breast cancer. 
In Paper I, we investigated the genome-wide assessment of c-Jun, a potent member of AP-1 
family, and ERα cistrome and transcriptome in ERα-positive breast cancer cells. Our findings 
demonstrate the genome-wide co-localization of ERα and c-Jun binding regions and suggest 
that ERα tethering to AP-1 is a global mechanism for gene transcription regulated by ERα. In 
addition, the results confirm that the sensitivity of ERα-positive breast cancer cells to 
tamoxifen therapy is reduced by c-Jun overexpression. Moreover, it is shown that expression 
of transforming growth factor β induced (TGFBI) protein is associated with poor outcomes of 
ERα-positive breast cancer patients receiving endocrine therapy and thus as a candidate gene 
that may cause tamoxifen resistance through ERα and AP-1 crosstalk. 
In Paper II, we elucidated the first Fra-1 associated interactome in triple-negative breast 
cancer (TNBC) cells using Rapid Immunoprecipitation Mass Spectrometry of Endogenous 
proteins (RIME) approach, showing that the most enriched Fra-1 interacting protein was 
DDX5. The cistrome and transcriptome of DDX5 extensively overlapped with that of Fra-1, 
which is highly associated with the TNBC cell growth. Furthermore, we found that DDX5 
acts as a transcriptional coactivator for Fra-1, enhancing Fra-1-dependent TNBC cell 
proliferation through increasing the transcriptional activity of Fra-1. We also showed that 
higher expression level of DDX5 protein was detected in triple-negative basal-like tumors 
compared with that in non-basal-like ones. In addition, the direct target gene set of DDX5 can 
predict poor clinical outcome of breast cancer patients. 
In Paper III, we generated a novel breast cancer cell model with overexpression of ERβ in the 
absence of ERα. We used CRISPR/Cas9 system to knock out ERα in MCF7 breast cancer 
cells with stable Tet-Off-inducible ERβ expression. We found that only ERβ-expressing 
MCF7 cells displayed a significant reduction in cell proliferation in response to E2 compared 
  
with vehicle, conversely, only ERα-expressing MCF7 cells displayed an increased cell 
proliferation upon E2 treatment. The RNA-seq results indicated that ERβ could modulate 
specific gene expression profile different from that of ERα. Furthermore, functional 
enrichment analysis showed that the two ER isoforms regulate cell proliferation in opposite 
direction; ERβ is significantly involved in the biological process “negative regulation of cell 
proliferation”. 
In conclusion, the studies presented in the thesis contribute to comprehensive understanding 
of the mechanism of ER and AP-1 signaling in breast cancer. We characterized two 
molecules, TGFBI and DDX5, in breast cancer, suggesting that they could be the candidates 
of therapeutic targets. We also provided evidences that ERα and ERβ have opposite effects 
on E2-dependent breast cancer cell proliferation by regulating distinct gene sets. 
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1   INTRODUCTION  
1.1   BREAST  CANCER  
Breast cancer is a malignant tumor arising from the cells in breast, and is the most frequent 
cancer among women around the world [1, 2]. GLOBOCAN 2018 database reports that the 
estimated number of new cases for breast cancer was more than 2 million among women, 
accounting for 24.2% of all new cancer cases in women [3]. Various risk factors and the 
usage of mammography can influence the patterns of global incidence [4]. The highest 
female breast cancer incidence rates (age-standardized) are in Australia and New Zealand, 
Western and Northern Europe and North America, while lowest rates are in most regions of 
Africa and Asia [5]. With the development of treatment and diagnostic techniques for breast 
cancer, the mortality rates have decreased. For instance, in the United State, breast cancer 
death rates decreased by 39% from 1989 to 2015, and the five-year survival rate has 
increased from 63% in 1960 to 90% in 2018 [6, 7]. However, breast cancer remains the major 
cause of death for women, with 15% of breast cancer-related deaths around world [4]. 
Especially in the developing low-income and middle-income countries, breast cancer 
mortality is high [4, 8, 9].  
1.1.1   Risk  factors  for  breast  cancer  
Along with the increased age, the incidence and mortality rates of breast cancer increase 
proportionally. Globally, the patients of breast cancer have a sharp incline beginning at age 
40 and reach a peak at around age 60 [10]. Currently, among the causes of cancer-related 
deaths, breast cancer becomes the leading one for young woman (under 45 years old). In 
USA, about 10,000 women with age less than 40 are diagnosed with invasive breast cancer 
[11]. In Asia, 13% of women diagnosed with breast cancer are less than 40 years of age, 
while 5% are less than 35 years [12]. As breast cancer has a genetic component, family 
history is another important risk factor. The risk of women to develop breast cancer increases 
with the number of affected relatives, particularly with the first-degree relatives [13, 14]. The 
hereditary breast cancer characterized with the mutations in high-penetrance genes, such as 
BRCA1 and BRCA2, constitutes 3-6% of all breast cancers [15]. Reproductive factors (early 
menarche (<12 years old), late age at first full-term pregnancy (>30 years old), nulliparity and 
late menopause (>55 years old)), menopausal hormone therapy and breast characteristics 
(personal history of breast cancer (<40 years), ductal or lobular carcinoma in situ and 
increased mammographic breast density) increase the risk for breast cancer [11, 16]. 
Moreover, some lifestyle and environmental factors that are risk for breast cancer to develop 
are alcohol consumption, lack of physical activity, obesity (postmenopausal) and radiation 
exposure to chest, etc. [10, 17]. 
1.1.2   Molecular  classification  of  breast  cancer    
The purposes of classifications of breast cancer, according to different criteria, are to 
diagnose and management the disease accurately. Breast cancer is traditionally classified by 
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the clinicopathologic features, including histopathological type, tumor grade and tumor stage 
(TNM), and biomarker receptor status, together with the characteristics of patients (e.g. age 
and menopausal status) [18, 19]. 
The advent of high-throughput technologies for gene expression analysis has considerably 
influenced our understanding of breast cancer biology. Global gene expression profiling 
(GEP) studies are used to classify breast cancer into four intrinsic subtypes by hierarchical 
clustering analysis [20-22], including luminal A, luminal B, human epidermal growth factor 
receptor 2 (HER2, also called ERBB2)-enriched and basal-like tumor. Subsequently, 
immunohistochemistry (IHC)-based surrogate molecular classification is applied in the daily 
clinical practice, because the IHC surrogate biomarkers (ER, PR, HER2 and Ki-67) are 
correlated well with these intrinsic subtypes and IHC approach is a low cost and widely used 
technique [23, 24]. Comparing with GEP-based classification, IHC-based classification can 
divide breast cancer patients into similar subgroups of clinical outcomes [24]. However, some 
discrepancies exist between these two classifications. For instance, basal-like subtype is often 
identified as triple negative breast cancer (TNBC) in clinical practice because a majority of 
basal-like subtype tumors are typically negative for ER, PR and HER2 defined by IHC. These 
two terms share considerable and significant overlap but not complete. Several studies 
reported that around 70% of IHC-based TNBCs were GFP-based intrinsic basal-like subtype, 
while 18-40% of basal-like breast cancers were not triple-negative immunophenotype [25-27]. 
The details about intrinsic subtypes are shown in Table 1. 
Table 1. Breast cancer molecular subtypes 
 
In total, breast cancer is a heterogeneous disease with different histological and biological 
properties. Molecular classification provides convincing proof supporting the relevance of 
histopathologic features in the underlying tumor biology. Therefore, histopathologic 
classification should be used together with molecular classification. Furthermore, gene 
expression profiling can provide more detailed biological characterization of genomic 
alterations associated with precise prognostication and risk stratification, which is useful for 
identifying novel targeted treatment for individual breast cancer patient. 
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1.1.3   ER-­positive  breast  cancer  and  endocrine  therapy  
The seminal class-discovery studies indicated that ER-negative and ER-positive breast 
cancers, in molecular terms, are primarily distinct diseases [20, 21]. ER-positive breast 
cancers fall into the luminal A and B subtypes, accounting for about 70% of breast cancer. 
Luminal A accounts for 50-60% of invasive breast cancers and is the most common 
molecular subtype. Luminal A breast cancers are of low histological grade and have the best 
prognosis among all intrinsic subtypes [28, 29]. The breast cancers of luminal B subtype 
make up 10-20% of all breast cancers. The main biological distinction between the luminal A 
and B is the expression level of proliferation genes, for example, luminal B has higher 
expression levels of MKI67 and cyclin B1 and also often expresses EGFR and HER2 [30].  
Clinically, luminal A breast cancers are more likely to respond well to endocrine therapy 
alone [31]. On the other hand, luminal B tumors have increased proliferation and they are 
more likely to recur with endocrine therapy alone, while they are likely to be more chemo-
sensitive. Thus, chemotherapy is recommended in addition to endocrine therapy for luminal 
B breast cancer patients [32]. Meta-analyses have demonstrated the benefits of adjuvant 
chemotherapy in reducing recurrence and breast cancer mortality, especially, with a greater 
magnitude of benefit in those with ER-negative disease, but the absolute benefits may be 
small and not worth the added risk of toxicity among women who have a baseline low risk of 
recurrence [33]. 
Endocrine treatment is a pivotal treatment for women with ER-positive tumors. The majority 
of endocrine therapies are to inhibit breast tumor growth through depriving the cell of 
estrogen or blocking its receptor [34]. Anti-estrogens (such as Tamoxifen and Fulvestrant) 
and aromatase inhibitors (AIs) are currently used to treat ER-positive breast cancer. 
Tamoxifen, as one of the selective ER modulators (SERMs), acts as antagonist binding to the 
ER to block estrogen from attaching to the receptor. Currently, tamoxifen is still one of the 
frontline and most successful drugs used in pre- and postmenopausal women. Furthermore, it 
displays a significant long-term benefit for treated patients [35]. For instance, a meta-analysis 
of 20 trails reported that adjuvant tamoxifen treatment reduces the risk of recurrence by 
nearly 50% during year 0 to 4 and more than 30% during year 5 to 9 [36]. Furthermore, the 
breast cancer mortality was reduced by around 30% throughout the first 15 years [36].  
Fulvestrant is a selective ER down-regulator (SERD), which competitively inhibits estradiol 
binding to ER and once it binds to ER induces degradation of ER by inhibiting receptor 
dimerization [37]. Compared with tamoxifen, fulvestrant has a higher binding affinity to the 
ER, 89% of that of estradiol [38], and it acts as a pure anti-estrogen [37]. Fulvestrant has 
already been introduced as a second-line agent for postmenopausal women with advanced 
breast cancers [39, 40].  
AIs inhibit the endogenous synthesis of estrogen by blocking the activity of aromatase. The 
third-generation AIs include two classes: steroidal AIs (exemeatane) and non-steroidal AIs 
(letrozole and anastrozole). AIs are mainly used in postmenopausal women as alternatives to 
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tamoxifen, and also as options for secondary strategy after tamoxifen [41-43]. For 
premenopausal patients with ER-positive breast cancer, ovarian function suppression 
combined with AIs or tamoxifen is more effective than tamoxifen alone [44]. 
1.1.4   HER2-­enriched  breast  cancer  and  related  adjuvant  therapy  
HER2-enriched subtype belongs to ER-negative breast cancers based on gene expression 
profile, since it is characterized by low or absent gene expression of ER and related genes, 
and overexpression of HER2 and genes located in HER2 amplicon at chromosome 17q12 
(e.g. GRB7) [19]. This subtype of breast cancer is highly proliferative, likely to be of high 
histological grade and P53 mutation and has an aggressive clinical outcome [18]. Not all 
GFP-based intrinsic HER2-enriched tumors are clinically HER2-positive defined by IHC, 
and a minority of clinically HER2-positive cancers co-expressing ER is classified as intrinsic 
luminal B subtype [45, 46].  
For HER2-positive breast cancers, the reasonable adjuvant treatment options include 
chemotherapy and anti-HER2 targeted therapy [34, 47]. For instance, one of the first-line 
treatments for HER2-positive metastatic breast cancer is trastuzumab, a monoclonal antibody 
that is directed against HER2 [48]. Furthermore, this therapy has dramatically improved 
overall survival and disease-free survival in HER2-positive breast cancers [48-50]. However, 
de novo or acquired resistance is still observed in 66-88% of HER2-positive metastatic breast 
cancer [51]  
1.1.5   TNBC  breast  cancer  and  related  adjuvant  therapy  
Although the terms of basal-like and TNBCs have been used interchangeably in past years 
and basal-like subtype predominates in triple-negative tumors, there is a small group of non-
basal-like subtype [19, 52]. Recently, according to comprehensive gene expression profile 
analysis, TNBCs patients are dived into four distinct subtypes; two were basal-like (BL) but 
with differences in immune response, one mesenchymal (M), and one luminal androgen 
receptor (LAR) subtype [53, 54]. Furthermore, the majority of the two BL and M subtypes 
are basal-like identified by PAM50, while LAR is non-basal-like, enriched in HER2 and 
luminal subtypes [19, 53, 54].  
TNBC is a biologically heterogeneous disease, representing 10%-20% of all invasive breast 
cancers.  According to previous literatures, the main characteristics of TNBCs are similar to 
that of basal-like cancers; TNBC is significantly more aggressive than other molecular 
subtypes, for example, TNBCs have more advanced stage and poor survival than non-TNBC 
subtypes regardless of the stage at diagnosis [55-57]; TNBCs are more likely to have both 
local and distant recurrence and metastases, such as brain and lungs [58]. Furthermore, 
women at younger age (<50 years old) and of African American race have been identified as 
having higher risk for TNBCs [25, 59, 60]. BRCA1 mutations appear to be a risk factor that 
causes basal-like breast cancers and a subgroup of triple-negative tumors [52, 61-63]. 
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Currently, the diagnosis of TNBCs has direct clinical implications and is important for tumor 
management. Cytotoxic chemotherapy remains the major therapeutic choice for TNBC 
patients, because they lack the expression of the appropriate targets (ER, PR or HER2) for 
endocrine therapy or anti-HER2 agents [64]. Chemotherapy leads to an initial substantial 
response rate, whereas it is often followed by poor outcomes, such as frequent relapses and 
lower overall survival [59, 65, 66]. Altogether, the above urgent necessitates the identification 
of novel therapeutic strategies for TNBC patients. Currently, poly (ADP-ribose) polymerase 
(PARP) inhibitors, androgen receptor antagonists, immune checkpoint inhibitors and some 
others are target therapies in study, which are used as monotherapy or together with other 
standard or investigational agents [64, 67]. 
1.1.6   Endocrine  resistance  
Although the endocrine treatments mentioned above for ER-positive breast cancer patients 
have led to substantial improvements in outcomes, either intrinsic or acquired resistance 
limits their benefits. For example, acquired endocrine-resistant disease may represent up to 
one-quarter of all breast cancers [68-70]. Moreover, the agonist effect of tamoxifen may 
induce a risk of endometrial cancer after long-term use in postmenopausal women [71]. 
Generally, AIs and fulvestrant are used to follow or replace when patients are resistant to 
tamoxifen [71, 72]. However, resistance to AIs and fulvestrant eventually occurs [73-75]. 
The progression of endocrine resistance is recognized as a gradual and step-wise process. 
Additionally, due to the complex biology of ER, multiple molecular mechanisms could 
underlie endocrine resistance (Figure 1). Mutations of ER [76] and crosstalk between ER and 
other signaling pathways (e.g. EGF/EGFR/HER2 pathway) are considered to be major causes 
of endocrine resistance [77, 78]. In addition, substitution of ER function by androgen receptor 
(AR), the upregulation of ER coactivators and alterations in corepressors, downstream 
signaling pathways and transcription factors (e.g. AKT/PI3K/mTOR, MAPK and NF-kB), 
overexpression of key cell-cycle regulators, as well as stem cell and immune system could 
contribute to endocrine resistance [70, 71, 79]. Although several mechanisms have been 
proposed, the complete and precise explanation behind the phenomenon of endocrine 
resistance cannot be defined by any of them to date.  
Recently, multiple targeted agents are used to overcome endocrine resistance, including the 
use of inhibitors for cyclin-dependent kinases 4 and 6 (CDK4/6), mammalian target of 
rapamycin (mTOR), PI3K/AKT and histone deacetylase, as well as investigation of new 
SERDs/SERMs [70, 72, 80]. In addition, it has been shown that HER2 inhibitors combined 
with endocrine therapies contain clinical benefit [79].  
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Figure 1. Hypothesized molecular mechanisms of endocrine resistance. 
1.2   ESTROGEN  RECEPTORS  
Estrogen receptors (ERs) belong to the superfamily of nuclear receptors that act as the ligand-
inducible transcription factors. ERs include two different members, ERα and ERβ. ERα was 
the first identified in the 1960s [81] and was cloned in 1986 [82-84]. Subsequently, ERβ was 
identified and cloned in 1996 from the rat prostate and ovary [85]. Although ERα and ERβ 
proteins are encoded by separate genes called ESR1 (on 6q25.1) and ESR2 (on 14q23), 
respectively, they have similar overall domain structures.  
1.2.1   Structures  and  functions  
ER proteins are comprised of six structural domains named from A to F [86] (Figure 2). A/B 
domains compose the N-terminal domain, which contains the transcription activation 
function-1 (AF-1). The role of AF-1 is regulating transcription activation of targeted genes 
ligand-independently via phosphorylation [87]. The C domain, the DNA binding domain 
(DBD), can mediate the binding of ERs to specific DNA sequences, such as estrogen 
response element (ERE). DBD is composed of two zinc-binding motifs and each motif 
includes an α-helix. The first motif, P-box, determines the DNA-binding specificity, such as 
the interaction with ERE. The second one contains D-box, which is important for receptor 
dimerization [88]. The D domain (hinge region) contains a nuclear localization sequence and 
acts as a flexible connection between DBD and ligand-binding domain (LBD) [89]. The E 
domain of ERs is the LBD, which consists of 12 helices that hold a dimerization interface, a 
hormone-binding site and a ligand-dependent coregulator interaction function (activation 
function 2, AF-2) [89, 90]. F domain following LBD on the far C-terminal and its functions 
are not fully understood. The F domain of ERα may be able to modulate the activation of 
transcription, dimerization, interaction of coactivators, and stability of the receptor [88, 91, 
92]. ERα and ERβ are highly conserved in the DBD (~95%) and LBD (~60%), but the N-
terminal domains and hinge region of two ERs share only ~15% and ~35%, respectively. 
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Figure 2. Structure of ERα and ERβ proteins. The letters from A to F represent six functional 
domains. The numbers on the right side are the total size of protein in amino acids (aa). The 
numbers (%) on the bottom mean the homology between ERα and ERβ domains. 
ERα and ERβ have tissue- and cell-type-specific expression profiles throughout the body. 
ERα is mainly found in various tissues, including uterus, ovary, breast, kidney, liver, bone 
and white adipose tissue [93]. ERβ has been reported to express in the ovary, lung, prostate, 
colon, kidney, male reproductive organs, central nervous system, cardiovascular system, and 
the immune system [93]. The biological functions are distinct between ERα and ERβ with 
different expression patterns [94]. Furthermore, ERα and ERβ knockout mice models 
represent distinct phenotypes [94].  
Estrogen is the main natural endogenous ligand for ERs. As the female steroid hormone, 
estrogen plays an important role in female and male reproduction as well as other systems, 
such as immune, skeletal, cardiovascular, and central nervous systems [94, 95, 96].  The 
biological effects of estrogen are mediated by these two ERs [86]. Severe damages of 
reproductive functions are observed in ER knock-out (ERKO) mice models, for instance, 
both sexes ERα knock-out (αERKO) mice are infertile [97, 98]. Female ERβ knock-out 
(βERKO) mice show arrested folliculogenesis and subfertility, while male βERKO mice are 
fertile [99, 100]. However, the life of mice is possible without either or both ERs [97, 98]. 
The predominant estrogen in the body is 17β-estradiol (E2), which is an unselective ligand 
for ERα and ERβ with equal binding affinity.  
In addition, estrogen is also associated with many different diseases including a variety of 
cancers, obesity, metabolic disorder and more [101]. Moreover, estrogen exposure has been 
found to be strongly associated with increased risk for breast cancer development [102, 103]. 
Therefore, anti-estrogens or antagonists of ERs that could inhibit ER activity are the main 
choice for the ER-positive breast cancer treatment. For instance, fulvestrant is a pure 
antagonist for ERα. Except inactivation of both AF-1 and AF-2, fulvestrant can also impair 
receptor dimerization after binding with ERα [104]. However, tamoxifen can act on both ERs 
with agonist or antagonist effects in tissue-specific or cell-type specific manner [105]. 
Antagonists bind to ERs in a manner similar to estrogen, however, they induce a different 
conformation of LBD, resulting in recruitment of co-repressors, rather than co-activators, by 
inhibition of AF-2 [106]. Furthermore, the agonistic activity of tamoxifen, as seen in uterus, 
appears to be associated with the activation of AF-1 [87, 107].  Regarding ERα, the AF-1 
domain is actively involved in gene expression induced by agonists whereas the AF-1 domain 
of ERβ acts very weakly [108, 109].  
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1.2.2   Molecular  mechanism  of  ERs  
ERs regulate target gene expression through distinct pathways (Figure 3). The first one is the 
classical pathway of ER, ER is activated by ligands followed by dimer formation and direct 
binding to specific DNA sequence (ERE) located in or near the promoters of target genes 
through the DBD of ER, resulting in the recruitment of different transcriptional coregulators 
(coactivators or corepressors) to form a complex, which is responsible for the recruitment of 
transcriptional machinery, the modulation of chromatin structure and regulation of target 
gene expression [103]. Second, estrogen also modulates the expression of genes lacking 
ERE-like sequences, by a tethering mechanism, in which ligand-activated ER interacts with 
DNA indirectly via interacting with other transcription factors at their respective response 
elements, such as activating protein 1 (AP-1), stimulating protein-1 (Sp-1), nuclear factor-κB 
(NF-κB) as some examples [110, 111]. Furthermore, through the non-genomic pathway, 
membrane-localized ER can elicit a rapid response to ligands leading to activation of 
signaling transduction pathway in cytoplasm, such as PI3K/MAPK signaling pathway [87, 
110, 111]. Additionally, ERs can regulate target gene expression in a ligand-independent 
manner, in which ER binds DNA directly or indirectly following ER activation through 
phosphorylation by growth factor signaling and other protein kinases [112, 113]. 
 
Figure 3. Simple model of mechanism of ER signaling. No. 1 is a classical pathway, ligand-
activated ERs directly bind to specific DNA sequence, such as ERE; No. 2 is the tethered 
pathway, ligand-activated ERs interact with DNA indirectly via tethering with other 
transcription factors; No. 3 is the non-genomic pathway, membrane-localized ER activated 
by ligands results in activation of signaling transduction pathway in cytoplasm; No. 4 is the 
ligand-independent signaling, which is induced by membrane receptor signaling, such as 
growth factor (GF), with the result of phosphorylation of ER leading to the activation of ER 
binding with ERE. 
Based on the current literature of ER transcriptome, E2-regulated gene expression is largely 
unique to each ER subtype, with distinct signaling pathways for ERα and/or ERβ, 
respectively [93, 114-117]. The comprehensive genome-wide mapping of ER DNA binding 
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regions indicates substantial overlap of two ERs binding sites, while regions bound by ERα 
have distinct properties compared with ERβ binding regions, including genome landscape, 
sequence features and conservation [93, 118, 119]. 
1.2.3   The  role  of  ERs  in  breast  cancers  
Comparing with ERβ, ERα is a ‘classic’ and well-characterized ER. In normal mammary 
glands, the proportion of ERα-positive cells is generally low (10-20%) while the proportion 
increases in proliferative benign disease and low-grade ductal carcinoma in situ (DCIS) [103, 
120]. In vitro studies also show that ERα-positive cell lines are dependent on estrogen for cell 
growth [121]. On the other hand, the expression of ERα is one of the indicators of hormone-
dependent tumor growth. More than 50% breast cancers overexpress ERα and approximate 
75% of these are estrogen-dependent at diagnosis [122]. The studies of the correlation 
between ERα expression status and the outcomes of breast cancer patients have indicated that 
the expression of ERα is considered to be a good indicator for endocrine therapy and breast 
cancer survival [123]. However, ERα status is not considered to be a perfect marker for 
responsiveness to anti-estrogens [114]. Because only 70% of ERα-positive breast cancer 
cases respond to tamoxifen and, interestingly, about 5-10% of the ERα-negative breast 
tumors are sensitive to tamoxifen treatment [116, 124].  
Some studies have shown that ERβ could be a therapeutic target for those who have no 
response to tamoxifen and ERα-negative breast cancer patients [116, 125]. ERβ could be 
expressed in either ERα-positive or -negative breast tumors [120, 126]. In general, some 
studies indicate that ERβ may play a role as a tumor suppressor and may increase the 
sensitivity of ERα-positive breast tumors to tamoxifen [127-130]. However, in ERα-negative 
breast cancer tissue and cells, ERβ exhibits pro-growth and pro-survival activity [131]. 
Moreover, ERβ1 (wild-type ERβ) coexists with four ERβ variants (designated ERβ2 to ERβ5) 
that complicate elucidation of their physiological role and involvement in ER carcinogenesis 
[132]. ERβ1 is the one fully functional variant. Generally, it has been described that the 
expression of ERβ1 is downregulated or absent from high-grade breast tumors. However, 
some large cohort studies report no correlation between ERβ1 and clinical parameters, which 
suggests that ERβ1 is not a prognostic or predicting biomarker for breast cancer [116, 126]. 
Thus, the exact role of ERβ in human breast cancer remains unclear. The controversial roles 
of ERβ could be due to the lack of specific ERβ antibody, and different antibodies have been 
used in various labs. To develop highly selective and widely-used anti-ERβ antibodies 
remains a main challenge. One recent study has shown that only one anti-ERβ antibody 
(monoclonal PPZ0506) is selective for ERβ among 13 tested anti-ERβ antibodies [133]. 
1.3   ACTIVATOR  PROTEIN-­1  
Activator protein-1 (AP-1) is a transcriptional factor which was first identified in 1987, and 
was found to bind to specific sequence of cis-control element of human metallothionein 
(hMTIIA) promoter and also binds to the enhancer region of simian virus 40 (SV40) [134]. 
The same year, the specific sequence, 5’-TGAG/CTCA-3’, bound by AP-1 was discovered in 
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the promoters of hMTIIA and SV40, and also that the tumor promoter 12-O-tetradecanoyl 
phorbol 13-acetate (TPA) could strongly induce binding of AP-1 to this sequence, and thus 
this sequence was called TPA-response elements (TRE) [135, 136]. 
AP-1 is a dimeric complex comprising several protein families. The Jun proteins (c-Jun, JunB, 
JunD) and Fos proteins (c-Fos, FosB, Fra-1, Fra-2) are the major and early identified 
components of AP-1 proteins [137]. According to the specificity of DNA-sequence and 
heterodimerization with Jun or Fos proteins, some basic leucine zippers (bZIP) proteins are 
also included to the AP-1 protein family, such as activating transcription factor (ATF)/cAMP-
responsive element-binding proteins (CREB) (ATF1, ATF2, ATF3/LRF1, ATF4, ATF5, 
ATF6a/b, ATF7, B-ATF, ATFa0 and CREB), musculoaponeurotic fibrosarcoma (MAF) (v-
Maf, c-Maf, MafB, MafF, MafG, MafK and Nrl) and Jun-dimerizing partners (JDPs) protein 
families (JDP1/2) [138-144]. 
As AP-1 proteins belong to basic leucine zippers (bZIP) family, their protein structures 
contain a leucine zipper domain and a basic DNA-binding domain. The leucine zipper 
domain is required for the formation of homo- or heterodimers among various bZIP proteins. 
The DNA-binding domain is a known protein-DNA recognition motif and responsible for 
nuclear localization and DNA binding. Moreover, the specificity and stability of dimers 
formed by a variety of AP-1 proteins are also varied based on the composition of the leucine 
zipper [145, 146] (Figure 4). Except leucine zipper domain and DNA-binding domain, AP-1 
proteins also contain two other domains, the docking sites and the transactivation domain 
[147] (Figure 5 and 6). 
 
Figure 4. The bZIP domain on the DNA where AP-1 binds in form of an X-shaped 
heterodimer, resulting in an α-helical structure [148]. The bZIP domain of Jun and Fos is 
shown in blue and red, respectively. The DNA backbone is shown in yellow. Reprinted from 
Nat Rev Cancer, Nov 1, 2003, Vol 3, Issue 11, p859-68, Robert Eferl et al., AP-1: a double-
edged sword in tumorigenesis [146], Copyright 2003, with permission from Springer Nature 
(license number: 4665851267602).  
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AP-1 regulates gene transcription through interaction with two possible elements, TRE and 
CRE (cAMP response elements, 5’-TGACGTCA-3’), via a bZIP domain [139, 149]. The 
only difference between TRE and CRE is one nucleotide in the middle [149, 150].  
Jun proteins not only form homodimers but also form heterodimers with other members of 
AP-1 proteins. ATF proteins can also form homodimers [140]. However, Fos proteins do not 
have the ability to interact with DNA only by forming stable heterodimers with Jun proteins. 
For instance, previous studies have shown that the homodimer of c-Fos was found to be 
unstable in vitro and assumed that it could not exist in live cells [151, 152]. Interestingly, a 
recent study reported the evidence for the existence of stable c-Fos homodimers in live cells 
[153], but it is still not clear whether the c-Fos homodimer is functional or not. Furthermore, 
in vitro studies have shown that Jun/ Fos heterodimers have higher stability than Jun 
homodimers [150, 154].  
With the three members of Jun proteins, the Jun or Fos protein families can form 18 different 
homo- and heterodimers, and these dimers have the highest affinity to TRE and slightly lower 
affinity to CRE [151]. Jun/ATF heterodimers or ATF homodimers prefer to bind to CRE 
[155]. MAF proteins recognize another longer palindromic sequence, MAF-recognition 
element (MARE), which consists of TRE or CRE. Jun/MAF and Fos/MAF heterodimers 
prefer to interact with the sequence with half part of TRE or CRE and half part of MARE 
[143, 151, 156]. Thus, the promoter-binding specificity and affinity of AP-1 are affected by 
the alteration of AP-1 dimer composition. 
Moreover, AP-1 transcription factors have essential effects on various cellular processes, 
such as proliferation, differentiation, apoptosis and inflammation [146, 147, 154]. A variety 
of cellular stimulation, including growth factors, cytokines, UV radiation, bacterial and viral 
infection and cellular stress, is able to regulate AP-1 transcriptional activity [147]. The dimer 
composition is critical to regulate activity of AP-1 proteins resulting in regulation of specific 
target genes [142]. For example, some studies found that the ratio of c-Jun/c-Fos and c-
Jun/ATF2 dimers existing in cells is able to determine the cellular response to apoptotic or 
oncogenic stimuli [157, 158].  
1.3.1   The  expression  and  functions  of  Jun  family  
The proto-oncogene c-Jun was first isolated and identified as a human counterpart of the viral 
homolog in the avian sarcoma virus 17 encoded oncogene, v-Jun, by Vogt and colleagues 
[137, 150]. Then the group of Dan Nathans identified other two Jun family members (JunB 
and JunD) [159, 160] (Figure 5). The gene of c-Jun is intronless, located on chromosome 1 
(1p32-p31) [161] while JunB and JunD both maps to chromosome 19.  
c-Jun gene is expressed at low levels in many cell types, but it is rapidly induced by exposure 
to different extra-cellular signals. There is a feedback loop in AP-1 activating c-Jun promoter, 
in which c-Jun can auto-regulate its own expression [162]. Moreover, similar to other AP-1 
family members, the activation of c-Jun is also regulated by post-translational regulation, 
especially phosphorylation via c-Jun N-terminal kinases (JNKs) or the kinases ERK1, ERK2 
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and GSK3β [142] (Figure 5). JNKs have been demonstrated to be important for c-Jun 
phosphorylation in response to cellular stress and for a basal level of c-Jun expression [163]. 
JNKs phosphorylate c-Jun on Ser 63/73 and Thr 91/93 residues at its transactivation domain 
leading to regulation of the transactivation activity [164]. In addition, phosphorylation of c-
Jun by JNKs can protect c-Jun from degradation by ubiquitination and hence increase the 
half-life of the protein [155, 165].  
Although the structures of JunB and JunD are similar to c-Jun, JunD lacks the JNK docking 
site while JunB does not have JNK phosphorylation sites [166]. Thus, JNKs phosphorylate 
JunD less efficiently and the phosphorylation activation of JunB is independent of JNKs. 
 
Figure 5. Schematic presentation of the structure of Jun protein family. Jun proteins contain 
several domains, including bZIP domain (basic region and leucine zipper), transactivation 
domains and docking sites for several kinases, while JunD lacks the JNK docking site. 
The three members of the Jun protein family are distinct in their biological function [146, 
155]. Previous mouse genetic studies have indicated that c-Jun and JunB are essential for 
normal mouse embryonic development. The c-Jun-deficient mice die between embryonic 
days E12.5 and E13.5 [167]. Lack of JunB causes embryonic lethality between E8.5 and 
E10.0 [168]. However, JunD -/- mice are viable and appear healthy [119]. Moreover, JunB 
can rescue c-Jun-/- mice embryo phenotypes dose-dependently and also partially replace the 
role of c-Jun in the regulation of c-Jun gene expression [169].  
Overexpression of Jun family members is found in many human cancers [142, 147, 170]. The 
expression of c-Jun plays an important role in tumor development, such as in liver, skin and 
breast tumors [146, 171]. Generally, c-Jun exhibits oncogenic functions. For example, it has 
been reported that c-Jun positively regulates the growth and angiogenesis of solid squamous 
cell carcinomas [172], and c-Jun works together with p53 to protect liver tumor cells from 
apoptosis [173]. Moreover, c-Jun is involved in tumor cell migration, invasion and epithelial-
mesenchymal transition (EMT) [174, 175]. However, JunB has been shown to exhibit dual 
roles [155]. It has been shown that JunB is overexpressed and involved in human cancers. For 
instance, a study suggests that JunB cooperates with c-Jun in mediating TGFβ-induced genes 
associated with invasion and cancer progression [176]. In contrast, JunB as a tumor 
suppressor has been shown in several in vivo studies [177, 178] and also acts oppositely to the 
role of c-Jun in cell proliferation [179, 180]. Furthermore, the biological activities of JunD 
are often opposite and antagonistic to c-Jun activities [155].  A study found that in prostate 
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cancer cells, overexpression of JunD increases the proliferation rate while overexpression of 
c-Jun and JunB decreases the proliferation rate [181]. 
1.3.2   The  expression  and  functions  of  Fos  family  
The Fos protein family consists of four members, including c-Fos, FosB, Fos related antigen-
1 (FosL1 or Fra-1) and Fos related antigen-2 (FosL2 or Fra-2) (Figure 6). The proto-
oncogene c-Fos was discovered as the human homolog of the retroviral oncogene v-Fos in 
the osteosarcoma virus and its expression can induce cellular transformation in rat fibroblasts 
[182, 183]. FosB gene was first identified with growth factor stimulation and indicated that 
FosB interacts with c-Jun and JunB proteins result in increase of their DNA binding activity 
[184]. Fra-1 and Fra-2 genes were isolated by screening human cDNA library from serum-
stimulated rat fibroblasts [185, 186]. 
c-Fos and Fra-1 are the most studied Fos proteins, and the former one is the prototype of Fos 
family. Except common domains (bZIP domain and DNA binding domain) shared among 
AP-1 proteins, c-Fos and FosB proteins have a C-terminal transactivation domain (Figure 6). 
This domain functions in transcriptional activation, stabilizing the pre-initiation complex and 
facilitating its assembly, and it is critical for the transformation capacity of Fos proteins [187, 
188]. However, Fra-1 and Fra-2 lack this domain. Due to Fos proteins having no ability to 
form homodimers, they need the dimerization partners, Jun proteins, which mainly influence 
their role in gene activation [144, 189]. Like Jun family members, c-Fos and FosB are also 
immediate early genes which have rapid and transient transcriptional activation in response to 
mitogenic stimulation or cellular stress [190, 191]. However, the increase of Fra-1 and Fra-2 
expression is delayed and stable compared with that of c-Fos and FosB [187].  
 
Figure 6. Schematic presentation of the structure of Fos protein family. All Fos proteins 
contain bZIP domain (basic region and leucine zipper). c-Fos and FosB proteins also have 
transactivation domains at C-terminal. 
Fra-1 knockout mice show embryonic lethality between E10.0 and E10.5, and Fra-2 knockout 
mice die shortly after birth, indicating the important role of these two proteins in mouse 
development [192, 193]. Several other mouse model studies have shown that Fos family 
proteins play an important role in normal tissue and tumor development [146, 154, 194]. For 
example, overexpression of Fra-1 and Fra-2 in transgenic mice results in the development of 
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lung tumors and epithelial tumors, respectively [195]. Moreover, c-Fos and Fra-1 are 
frequently overexpressed in tumor cells or tissue [195-197]. Further studies show that c-Fos, 
Fra1 and Fra2 might involve in the invasion process of breast cancer [154, 198, 199]. FosB 
has been shown to be highly expressed in normal mammary epithelia but downregulated in 
poorly differentiated mammary carcinomas [198, 199]. Recent evidences have shown that 
Fra-1 is a key regulator to drive EMT and hence increases invasive and metastatic capabilities 
of tumor cells [200]. However, there are some studies indicating that c-Fos has a tumor 
suppressor activity in various cancer types, such as gastric carcinoma, hepatocellular 
tumorigenesis and epithelial ovarian carcinoma [201-203]. 
The activity of Fos family proteins is also modulated by phosphorylation via different kinases, 
including MAPK, RSK, ERK, PKA or PKC, to influence protein stability, DNA-binding 
activity, transactivation and transforming activity [154, 204, 205]. c-Fos and Fra-1 are 
degraded through the N-terminal destabilizer domains by ubiquitin dependent mechanisms 
and they also, like Fra2 and FosB, undergo a ubiquitin-independent degradation by 
proteasome [206-208]. 
1.3.3   The  role  of  AP-­1  in  breast  cancer  
AP-1 is a key component of various signal transduction pathways, and it regulates various 
cellular events including proliferation, differentiation, survival, angiogenesis, migration and 
invasion [146]. The activity of AP-1 is enhanced in numerous human tumor types, thereby 
playing a key role in tumorigenesis [209]. 
In breast cancers, AP-1 family members are important regulators of cell growth through 
multiple mechanisms. AP-1 blockade inhibits breast cancer cell growth induced by many 
factors, such as estrogen, epidermal growth factor (EGF), heregulin (HRG) and insulin-like 
growth factors (IGFs) [210]. In line with this, an in vivo study reported that blocking AP-1 in 
established breast tumors suppresses its growth in nude mice [210]. Furthermore, a study 
indicated that AP-1 regulates the expression of cyclin D and E2F and their target genes to 
mediate the cell cycle and cell proliferation of breast cancer cells [211, 212].  
In addition, it has been shown that AP-1 is overexpressed in the aggressive subtype of breast 
cancer, such as TNBC/basal-like, compared with ERα-positive breast cancer [170, 213, 214]. 
High AP-1 expression is associated with poor prognosis of breast cancer. For example, 
analysis of cDNA microarray data including 197 breast cancer patients showed that high 
expression of Fra-1 significantly correlates with shorter overall survival and higher 
percentage of lung metastasis in ERα-positive breast cancer patients [215]. Moreover, a role 
for Fra-1 or c-Jun in promoting breast cancer cell metastasis in vivo has been demonstrated in 
a zebrafish tumor xenograft model [214], and Fra-1 has been identified as a key regulator 
involved in the process of metastasis in rodent model systems [216]. In addition, it has been 
shown that AP-1 is a key regulator of inflammation-induced cancer progression and also 
involved in the inflammation-induced EMT in TNBC [217, 218]. 
  15 
Clinically, it has been shown that transcriptional responses of AP-1 were increased in 
tamoxifen resistant ERα-positive breast cancer [219]. Additionally, tamoxifen resistance is 
also associated with increased JNK activity [220]. Furthermore, the ER/AP-1 cross-talk plays 
an important role in tamoxifen resistant breast cancer. The stress-related kinases and growth 
factor receptors (GFRs), both of which are upstream of AP-1, are implicated in breast cancer 
with endocrine resistance [221]. A previous study reported that tamoxifen was a potent 
transcriptional activator of ERβ at an AP-1 site [222]. Moreover, reprogramming of ERα 
nuclear genomic function through its binding to AP-1 sites might be a feature of endocrine 
therapy resistance [221]. Together, AP-1 and/or its signaling pathways could serve as entry 
points for targeted therapies for breast cancers. 
Several compounds, including synthetic inhibitor and bioactive compounds, have been 
identified based on the mechanism of AP-1 inhibition [209, 223]. T-5224 is a selective AP-1 
inhibitor initially investigated for the treatment of rheumatoid arthritis in phase II human 
clinical trials. However, this was ceased for unreported reasons in 2008 [144]. T-5224 shows 
no effect on AP-1 protein expression over several time points but specific inhibition of DNA 
binding activity of c-Fos/c-Jun, whereas other transcription factors like MyoD, Sp-1, NF-
κB/p65 remain unaffected [224]. Nevertheless, most currently identified compounds lack 
specificity and thus today no effective inhibitors against AP-1 have been approved for 
application in the clinics [223]. 
1.4   TRANSFORMING  GROWTH  FACTOR  b  INDUCED  (TGFBI)  PROTEIN  AND  
BREAST  CANCER  
TGFBI protein is a transforming growth factor β inducible secreted extracellular matrix 
(ECM) protein. This protein was originally known as βig-h3, because its gene (TGF-β-
induced gene-human, clone 3, βig-h3) was first identified from a cDNA library of a human 
lung adenocarcinoma cell line A549 treated with TGF-β [225, 226]. This gene is located on 
the chromosome 5q31 and encodes a 683-amino-acids, and the predicted molecular mass of 
TGFBI secreted form is 68kDa. TGFBI protein contains an N-terminal secretory signal 
peptide (SP), a cysteine-rich domain (CRD), four consecutive fasciclin-1 (FAS1) repeats, 
which contain several known integrin-binding motifs (e.g. NKDIL, YH18, and EPDIM), and 
a C-terminal Arg-Gly-Asp (RGD) integrin-binding motif [227, 228]. 
TGFBI protein has been detected in most normal human tissues [229]. Although TGFBI is a 
downstream component of TGF-β signaling pathway, its expression is regulated not only by 
TGF-β, but also by other factors and mechanisms, such as autophagy [230], microRNAs 
[231], interleukin (IL)-1β [232], IL-4 [233], tumor necrosis factor α (TNFα) [232], cancer-
associated fibroblasts (CAFs) [234], and high glucose concentrations [235, 236]. TGFBI 
mediates cell adhesion, migration, proliferation, apoptosis, and angiogenesis through 
interaction with several ECM molecules (e.g. collagen, fibronectin, and laminin) and 
integrins (e.g. α1β1, α3β1, αvβ3, and αvβ5) [228, 235, 237-240]. The integrins are the major 
TGFBI cell surface receptors identified to date [227].  In addition, abnormal expressions of 
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TGFBI are associated with various diseases, including corneal disorders [241], diabetes [242] 
and many types of cancers [228, 236].  
The functions of TGFBI are dependent on the tumor cell type and microenvironment, and it 
has dual effects, including acting as tumor suppressor or tumor promoter [228]. Studying 
TGFBI knockout mice showed that lack of TGFBI displays a higher incidence of 
spontaneous tumor growth and chemical carcinogen-induced skin tumors compared with 
wild-type mice, suggesting that TGFBI acts as a tumor-suppressor [243]. In contrast, a recent 
study indicated that the role of TGFBI in gastrointestinal tract is as a tumor promoter, and the 
overexpression of TGFBI in mice induces spontaneous tumors [244].  
Regarding the tumor suppressor function of TGFBI, several studies reported that down-
regulation of TGFBI was identified in various tumors cells and correlated highly with its 
promoter hypermethylation [245, 246]. For example, the expression level of TGFBI protein is 
reduced and only trace amount is detected in breast tumor cell lines [229, 247]. In a study of 
Bingyan and colleagues [247], in vitro and in vivo experiments identified the suppressive role 
of TGFBI in the development of breast cancer cells via possible mechanisms, including 
suppression of cell proliferation, delaying of G1-S phase transition and induction of 
senescence. Moreover, it has been shown that TGFBI induces adhesion to ECM proteins, and 
inhibits metastatic ability both in vitro and in vivo [229].  
On the other hand, there are increasing data indicating that TGFBI exhibits a tumor-
promoting function. Overexpression of TGFBI has been noted in various tumor tissues and 
cell lines [227]. For example, recombinant TGFBI promotes mobility and invasiveness of 
ovarian carcinoma cells [248]. Furthermore, the increased TGFBI expression has been related 
to the aggressiveness of tumors [228, 240, 249]. Additionally, a gene expression profile 
analysis identified TGFBI mRNA levels to be relatively increased in two highly invasive 
breast cancer cell lines, including BT549 and Hs578T [250]. 
Previous studies have shown that the expression of TGFBI appeared to induce paclitaxel 
sensitization in ovarian cancer [251]. However, a microarray-based gene expression analysis 
identified high expression of TGFBI involved in topotecan-resistant ovarian cancer [252]. 
Moreover, it has been reported that TGFBI might be associated with Lapatinib resistance in 
HER2-positive breast cancer cell lines [253]. On the other hand, epigenetic silencing of 
TGFBI by DNA methylation has been found to contribute to the trastuzumab resistance in 
HER2-positive cell models [254]. Taken together, TGFBI can function as a chemo-sensitizer 
or a risk of chemo-resistance in various cancers.  
1.5   COREGULATORS  OF  TRANSCRIPTION  FACTORS  
The activity of transcription factors (TFs) and distinct expression patterns of genes regulated 
by TFs in different tissues are controlled by another class of molecules, known as the 
coregulators [255]. A majority of coregulators organized in large multi-protein complexes are 
recruited to the genome by DNA-binding TFs and thereby regulate (activate or repress) the 
transcription of specific genes [256, 257]. Transcriptional coregulators that enhance the 
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transcription activity are referred to as coactivators while those that repress the transcription 
activity are known as corepressors. Coregulators exhibit protein-protein interaction with TFs 
that bind to specific genomic loci [255]. Each complex of coregulators can be recruited to 
various TFs, and each TF can recruit many different complexes of coregulators [257].  
Many coregulators interact with nuclear receptors, such as ER, in a ligand- and AF-2-
dependent manner [258]. Most coactivators are recruited to ER through a conserved motif 
‘NR box’ with the sequence LXXLL (X, any amino acid; L, Leucine) [259]. For instance, 
steroid receptor coactivators (SRCs)/p160 are the primary coactivators of ERα and they 
contain NR box that interact with AF-2 domain to recruit to ER, followed by recruiting the 
secondary coactivator, including histone acetyltransferase (HAT), coactivator-associated 
arginine methyltransferase 1 (CARM1), CREB-binding protein (CBP)/p300, ATP-dependent 
chromatin remodeling complexes and many others [260]. 
Additionally, transcription corepressors interact with ER through LxxH/IIxxxI/L motif 
(CoRNR box; I, Isoleucine; H, Histidine) to inhibit its transcriptional activity [261, 262]. For 
example, Peohibitin (PHB) functions as a corepressor of ERα to inhibit ERα-mediated 
transcriptional activation in breast cancer cells and also interacts with histone deacetylases 1 
(HDAC1) [263]. Additionally, corepressors also exhibit negative function through a direct 
interaction with unliganded ER or by competing with coactivators for ER binding, such as 
receptor-interacting 140 (RIP140) that can antagonize coactivator SRC-1 and also recruit 
HDACs [113, 260]. ERs could also associate with other nuclear receptor corepressors, such 
as nuclear corepressor (N-CoR) [264, 265]. 
HATs or HDACs are one of the most studied enzymes. They form part of coregulator 
complexes and have essential roles in modifying chromatin. CBP/p300 interacts with almost 
all TFs and regulates gene expression by opening chromatin structure at the target gene 
promoter through the HAT activity [266]. Moreover, SRC-1 can form a complex with 
CBP/p300 that coactivates the AP-1 mediated transactivation [267]. CREB-related 
transcription coactivator 1 (CRTC1) acts as a coactivator through direct interaction with the 
bZIP regions of c-Jun and c-Fos to control AP-1-mediated transcriptional response to TPA 
[268]. In addition, several AP-1 target genes were proved to be occupied by N-CoR/SMRT 
corepressor complexes under basal conditions [269]. Many factors initially identified as 
nuclear receptor coregulators have been demonstrated to act as AP-1 coregulators [269].  
Thus, the full characterization of the nature and composition of transcription factor 
interacting protein complexes in cancer cells will provide essential information to understand 
how they control target gene specificity, cellular signaling and phenotypes, ultimately to 
identify their potential roles as therapeutic targets. 
1.5.1   DDX5  and  breast  cancer  
DDX5 (p68) is a member of the DEAD (Asp-Glu-Ala-Asp)-box family belonging to the 
RNA helicases. DDX5 was first identified as a nuclear antigen that cross-reacts with an 
antibody against the T-antigen of Simian Virus 40 [270]. The DEAD-box proteins contain a 
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helicase core that includes two domains at N- and C-terminal, respectively [271, 272]. The N-
terminal domain is comprised of motifs Q, I, Ia, Ib, II and III, and the C-terminal domain 
contains IV, V and VI motifs [273]. The nine conserved regions harbor for RNA binding, 
ATP binding and hydrolysis, and intermolecular interaction [274]. DDX5 shares 90% 
homology of the helicase core with another DEAD-box protein, DDX17 (p72), and these two 
proteins can form heterodimers in cells [275]. 
DDX5 protein is 69kDa with 614 amino acids encoded by DDX5 gene which is located on 
chromosome 17q23. The expression of DDX5 is ubiquitous in human tissues and plays 
multiple functions, including ATPase activity, RNA unwinding, transcription and RNA 
processing activities [273, 276, 277].  Moreover, DDX5 is involved in cell growth, early 
development and maturation of some organs [278-280]. Additionally, several experimental 
results reveal examples of diseases associated with DDX5, including obesity [281, 282], 
Down syndrome [283], myotonic dystrophies [284] and especially cancer [285, 286].  
With regards of cancers, DDX5 has a critical role in cancer development [286, 287]. The 
abnormal expression of DDX5 was identified in various cancers, including breast cancer 
[288], lung cancer [289], colorectal cancer [290, 291], colon cancer [292, 293], multiple 
myeloma [294], cutaneous squamous cell carcinoma [295], leukemia [296, 297] and head and 
neck squamous cell carcinoma [298]. Accordingly, DDX5 acts as a transcriptional 
coregulator for several cancer-associated TFs, such as AR [299], ERα [272, 300], tumor 
suppressor p53 [301], β-catenin [302, 303], MyoD [304], Runx2 [305], Notch transcriptional 
activation complex [306], NF-κB, and signal transducer and activator of transcription 3 
(STAT3) [306]. In addition, some studies have indicated that DDX5 also participates in the 
transcription initiation [301, 307, 308].  
DDX5 is frequently overexpressed in breast cancer, particularly in higher grade and poor 
prognosis breast tumors [300]. As a transcriptional coactivator of ERα, DDX5/DDX17 act as 
the key regulators of estrogen-signaling pathways by controlling both upstream and 
downstream of the ERα at transcriptional and splicing level [309, 310].  
Moreover, DDX5, a coactivator of b-catenin, functions in the expression of TCF4 mediated 
by Wnt signaling, which is a tumor promoting pathway, in breast cancer cells [273, 311]. The 
study of Guturi and colleagues [302] showed that in breast cancer, β-catenin/TCF4 and 
DDX5 constitute positive feedback loop that are essential for Wnt/β-catenin-signaling 
involved in tumorigenesis. On the other hand, β-catenin/TCF4 upregulates DDX5 expression 
leading to EMT in breast cancer cells [302]. 
STAT3 is functionally active in numerous cancers, particularly in half of the breast cancers, 
and has been confirmed to be constitutively active in TNBC [312, 313]. DDX5 has been 
reported to be a coactivator of STAT3 and upregulate the downstream genes of STAT3 
which are associated with a wide range of tumorigenic processes, such as cellular 
proliferation, survival, invasion and angiogenesis [306]. DDX5 also interacts with long non-
coding RNA (lncRNA), such as LOC284454, to modulate cancer-related pathways and 
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pathology of breast cancer, such as focal adhesion and cell migration [314]. Furthermore, 
post-translational modification of DDX5 can regulate the coactivation effects, especially 
phosphorylation of DDX5 at tyrosine residues has been shown to be associated with 
abnormal cell proliferation and cancer development [315]. 
In total, according to the above-described functions of DDX5 in breast cancer, DDX5 is 
considered to be an excellent candidate as therapeutic target [316]. More than that, the 
depletion of DDX5 enhances the sensitivity of HER2-positive breast cancer cells to 
trastuzumab [317]. A study has suggested that small molecule inhibitors could selectively 
target the activity of DEAD-box family members [286, 318]. The phosphorylation of DDX5 
at Tyr593 residue was previously identified only in transformed cancer cells, but not in 
normal cells [287]. Therefore, phosphorylated-DDX5 (p-DDX5) could be specifically 
targeted by anticancer molecule exhibiting strong growth inhibition, such as RX-5902 
(Supinoxin), which binds directly to p-DDX5 in cancer cells to inhibit the interaction 
between p-DDX5 and b-catenin pathway resulting in blocking the b-catenin pathway and its 
downstream genes (e.g. c-Jun, c-Myc and cyclin D1) [287, 319]. RX-5902 induced G2/M 
arrest and apoptosis in TNBC cells, and had additive effects of anti-tumor in vivo, currently, a 
phase 2 clinical trial in TNBC is ongoing (https://clinicaltrials.gov/ct2/show/NCT02003092) 
[320]. Further studies on the precise mechanism of DDX5 in cancer progression are essential 
to development of novel therapeutic approaches. 
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2   AIMS  OF  THE  THESIS  
The overall aim of this thesis is to comprehensively decipher the role of the ER and AP-1 
transcription factors in breast cancer, using functional genomics technologies that today can 
identify the cistrome, transcriptome and proteome at an unprecedented detail, thereby, this 
could further provide information for developing novel therapeutic strategies for breast 
cancer. In particular, the three specific aims were: 
I.   To explore the genome-wide overlap in DNA binding profiles of two transcription 
factors, ER and AP-1, and to understand their coordinated interaction at the genome 
level. 
II.   To identify the chromatin interactome of Fra-1 in TNBC cells and hence to detect 
some novel coregulators of Fra-1. 
III.   To provide a novel and valuable resource to further complement the knowledge of 
ERα or ERβ uniquely mediated gene transcription in ERα-positive breast cancer cells.  
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3   METHODOLOGICAL  CONSIDERATIONS  
The details of materials and methods are described in each constituent study. In this section, 
discussion of considerations and limitations of used methods are described as below. 
3.1   CELL  LINES  
Cell lines are easy to handle, and they also could grow infinitely and provide a consistent 
sample. Therefore, in cancer research, a majority of in vitro models are cell lines. However, 
there are several limitations for cell lines. Due to the extended period of cell culture, serial 
passage of cell lines can cause variation of genotype and phenotype and genetic drift, as well 
as lead to heterogeneity in cultures at a single point in time, which could cause the various 
results detected from the same subtypes and even the same cell line is different between 
different labs [321]. 
In this thesis, two groups of cell lines were used, including TNBC cells and non-TNBC cells, 
which were purchased from American Type Culture Collection (ATCC). In Paper I, we used 
MCF7 cells with inducible Tet-off system (Clontech) expressing AP-1 protein, because AP-1 
components, such as c-Jun and Fra-1, express at very low levels in available cell lines of ERα 
positive breast cancer [214]. We also used MCF7 cells with Tet-off induced expression of 
ERβ in Paper III, due to the fact that there were no ERα-positive breast cancer cell lines 
expressing significant levels of ERβ. Furthermore, we performed gene editing using 
CRISPR/Cas9 system on this cell model. We used four types of TNBC cells (BT549, Hs578T, 
MDA-MB-157 and MDA-MB-231) and eight non-TNBC cells (MCF7, T47D, MDA-MB-
175, MDA-MB-453, ZR-751, CAMA-1, HCC1569 and SK-BR-3). W.G. Coutinho and E.Y. 
Lasfargues isolated BT549 cells in the year of 1978. Because BT549 has high expression of 
AP-1 and transfection is easier compared with other TNBC cells, BT549 was chosen to be the 
representative cell model to study TNBC. 
3.2   TET-­OFF  GENE  EXPRESSION  SYSTEM  
Tet gene expression systems are used to regulate the activity of gene in eukaryotic cells [322]. 
Tet-off and Tet-on cell lines are commercial and provide a ready way to study the gene of 
interest at high expression level. In each system, there are two critical components, including 
tetracycline (Tet)-controlled transcription factor and response plasmid expressing interest 
gene.  
In Tet-off system, tetracycline-controlled transactivator (tTA) is from the fusion of E. coli Tet 
repressor protein (TetR) and Herpes simplex virus VP16 activation domain. The pTet-off 
regulator plasmid encodes tTA and the target gene expression of tTA is regulated under 
transcriptional control of a Tet-responsive promoter element. In the absence of Tet or 
doxycycline (Dox), TetR part of tTA will bind to the Tet operator sequences (tetO) in 
tetracycline-responsive element (TRE) and further active the gene expression. However, 
when Tet or Dox is present, TetR will bind to Tet other than tetO sequences to inactive the 
gene expression (Figure 7A). Tet-on system is based on a reverse tTA (rtTA) generated by 
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altering four amino acids, which can only bind to tetO sequences in the TRE in the presence 
of Dox. Therefore, in tet-on system, the expression of the gene of interest is activated by rtTA 
only with Dox (Figure 7B). 
 
Figure 7. Schematic diagram of the Tet-off and Tet-on systems. The TRE locates at the 
upstream of the minimal immediate early promoter of cytomegalovirus (PminCMV), which 
keeps silent state without activation. A, In the Tet-off system, tTA binds to TRE without Tet 
or Dox that causes the activation of the gene transcription. B, The Tet-on system only 
responses to Dox. In the presence of Dox, rtTA can bind TRE and active transcription.  From 
Tet-Off® and Tet-On® Gene Expression Systems User Manual (Clontech Laboratories, Inc®). 
In this thesis, the genes of interest (AP-1 or ERβ) should be active, and only be turned off 
occasionally, so we used Tet-off gene expression system. 
Regarding the response plasmid expressing gene of interest, we used pBI-EGFP plasmid, 
which can coexpress the genes of interest (AP-1 or ERβ) and enhanced green fluorescent 
protein (EGFP) controlled via bidirectional promoter. The expression of the target genes can 
by monitored by EGFP expression using fluorescence-activated cell sorting (FACS) or 
fluorescence microscopy. The relative expression levels of target genes can be inferred at the 
levels of EGFP expression in the absence or presence of Tet or Dox (Figure 8). 
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Figure 8. Restriction map of pBI-EGFP. pBI-EGFP vector contains a bidirectional 
tetracycline-response promoter (Pbi-1). In the Tet-off and Tet-on systems, Pbi-1 is responsive 
to tTA and rtTA regulatory proteins, respectively. AP-1 or ERβ cDNA was cloned into the 
Multiple Cloning Site (MCS). From pBI-EGFP vector information (Clontech Laboratories, 
Inc®). 
3.3   CRISPR/CAS9-­BASED  GENE  EDITING  
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas is a microbial 
adaptive immune system. This system is used to cleave foreign genetic elements through 
RNA-guided nucleases. Among three identified types of CRISPR mechanisms, the type II 
system is the most studied and well characterized one, which can induce site-specific DNA 
cleavage by using noncoding RNAs to guide the Cas9 nuclease [323]. Through cellular DNA 
repair mechanisms, including the homology-directed repair (HDR) pathway or the non-
homologous end joining DNA repair pathway (NHEJ), to repair this DNA damage (Figure 9). 
The CRISPR/Cas9 system is a simple and precise RNA-programmable method which is 
applicated to regulate genome editing in a variety of mammalian cells and organism resulting 
in the gene knockins (via HDR) or knockouts (via insertion or deletion). 
In this thesis, we deleted ESR1 gene by NHEJ mutation pathway, resulting in insertions that 
disrupted the ESR1 locus. 
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Figure 9. Schematic of CRISPR/Cas9-based gene editing. The Cas9 nuclease is targeted to 
genomic DNA sequence through a guide RNA. The guide RNA contains a 20-nt guide 
sequence that pairs with the DNA target, immediately upstream of the protospacer-associated 
motif (PAM). This mediates a double-strand break (DSB) 3 bp upstream of the PAM. The 
DSB can be subsequently repaired by NHEJ or HDR pathway. Reprinted from Mol 
Neurodegener, Vol 10, Zhuchi Tu et al., CRISPR/Cas9: a powerful genetic engineering tool 
for establishing large animal models of neurodegenerative diseases [324], Copyright 2015, 
Used under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0).  
3.4   GENE  EXPRESSION  ASSAYS  
Gene expression can provide the information to interfere cellular signaling and cellular 
responses at an indicated time point. The following described assays were used in this thesis 
to target a single gene or at a genome-wide scale. 
3.4.1   Quantitative  polymerase  chain  reaction  
Quantitative polymerase chain reaction (qPCR) is a method to quantify gene expression in 
real time, which is also called real-time PCR. The amplification of DNA during PCR process 
can be detected in real time by using fluorescent reporter. The two major options of 
fluorescent reporter are intercalating dye and hydrolysis probe-based. The most common used 
intercalating dye is SYBR Green, which can bind to the DNA double helix to alter the dye 
structure and further make the dye to generate more fluorescence. Regarding the hydrolysis 
probes, e.g. Taqman probe, they are fluorescently labeled DNA oligonucleotides, a 
fluorescent reporter molecule at 5’end and a quencher molecule at 3’ end, which could bind 
to the downstream of the primer specifically during the PCR process followed by fluorescing. 
In this thesis, we choose SYBR Green dye to perform qPCR due to low cost when detecting a 
variety of different genes and most of our interested genes are abundant. Additionally, by 
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measuring the PCR efficiency, we confirmed that the SYBR Green dye amplified a single 
product using a melting curve and obtained the similar results as Taqman probe [325].  
qPCR is a very sensitive and powerful DNA analysis approach, it is ease of use and needs 
relatively short period of time for quantifying mRNA transcripts [326]. However, there are 
several limitations regarding qPCR. For instance, researchers need to acquire the information 
of the sequence of the target gene and the approach is a low throughput method.  
3.4.2   High-­throughput  gene  expression  analysis  
Gene expression microarray and RNA-sequencing (RNA-seq) are two main approaches to 
provide transcriptome-wide gene expression profiles for a sample. 
Since the development and application of microarray during mid-1990s, which made the high 
throughput gene expression analysis possible [327, 328]. Microarray can detect nucleic acids 
in a sample by hybridization to probes on microchips, which is ease of sample preparation 
and low cost per sample. However, microarray assay should base on the existing knowledge 
of genome sequence, and its dynamic range of detection is limited caused by both 
background and saturation of signals [329]. With the rapid development of next-generation 
sequencing from early 2000s, the application of RNA-seq offers an alternative method for 
gene expression studies. RNA-seq can directly determine cDNA sequence based on simple 
counting of reads. Thus, it could overcome some limitations of microarrays. Moreover, RNA-
seq has more applications, such as differential splicing analysis, detection of allele-specific 
expression and identification of novel transcripts [328]. The read depth is a key factor that 
influences the reliability of quantification of expression levels, and high variance is a 
character of low transcript abundances [330]. 
In the Paper I, we performed gene expression microarray by Affymetrix ClariomTM D arrays, 
which is a next-generation transcriptome-level expression analysis tool offering a fast path to 
results. This assay gets unprecedented coverage of all known transcripts, regardless of 
abundance, available for human, mouse and rat. Moreover, it is the most comparable method 
to RNA-seq because it offers strand specific hybridization and is able to detect low 
expressing transcripts, but unlike sequencing. In Paper II and III, we performed RNA-seq 
using Illumina HIseq technology. DESeq 2 workflow was performed to analyze the 
differential gene expression. 
3.5   CHROMATIN  IMMUNOPRECIPITATION  (CHIP)  
ChIP assay was the critical assay in the first two papers, Paper I and II, included in this thesis. 
This assay is used for probing DNA-protein interactions and identification of the specific 
genomic location of associated proteins in a living cell. By crosslinking the DNA and 
proteins in live cells, researchers can get snapshot information for specific protein-DNA 
interactions and quantitate the interaction by qPCR. In addition, this assay can also combine 
with high-throughput sequence technology, such as ChIP-seq, to provide the interactions at 
genome-wide scale [331, 332]. Integrating cistrome data paralleled with transcriptome data is 
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a powerful and comprehensive analysis to find out the role of DNA binding of distinct factors 
on gene expression.  
The reliability of ChIP experiment is mainly dependent on the quality and specificity of 
antibodies. In addition, the cell number and the range of chromatin fragments after sonication 
can also cause various results. 
3.6   RAPID  IMMUNOPRECIPITATION  MASS  SPECTROMETRY  OF  
ENDOGENOUS  PROTEINS  (RIME)  
To gain insight into the endogenous protein complex interacting transcription factor (in case 
Fra-1), we used RIME approach in Paper II, which was the critical and foundational 
experiment for the following study of Paper II. RIME was developed and optimized by 
Hisham Mohammed and colleagues [333] based on the strategy that combination of ChIP 
with mass spectrometry was applicated to study the composition of protein complexes 
associated with chromatin. Similar to regular ChIP described above, cells are crosslinked by 
formaldehyde, chromatin sheared by sonication and endogenous complexes 
immunoprecipitated by antibodies (Figure 10), followed by on-beads digestion, which can 
increase digestion efficiency and avoid antibody contamination. In addition, the assay has the 
ability of identifying endogenous protein complexes without engineering cells at either DNA 
or protein level.  
The method is enough sensitive for investigating the high affinity and transient interactions of 
complexes formed by low-abundance proteins. Similar with the main limitation of ChIP, it 
needs high-affinity and high-specificity antibodies to get high-quality results. 
 
Figure 10. RIME workflow. Protein-protein interactions are crosslinked followed by 
sonication to shear chromatin. Subsequently Fra-1 complexes are immunoprecipitated with 
Fra-1 antibody and Fra-1 interacting proteins are identified by mass spectrometry. 
  
  29 
4   RESULTS  AND  DISSCUSSION  
4.1   PAPER  I:  C-­JUN/AP-­1  OVEREXPRESSION  REPROGRAMS  ERa  
SIGNALING  RELATED  TO  TAMOXIFEN  RESPONSE  IN  ERa-­POSITIVE  
BREAST  CANCER  
Estrogen receptor has been shown to modulate gene expression through a tethering 
mechanism, in which ER interacts with other transcription factors (e.g. AP-1) and then 
binds to non-ERE sequence. However, the genome-wide overlap in DNA binding profiles 
of ERα and AP-1 transcription factors has not been reported.  
To be able to identify how ERα signaling interplays with AP-1 signaling at the molecular 
level in ERα positive breast cancer cell lines, we generated an MCF-7 cell line with Tet-
off-induced c-Jun protein expression. The expression and intracellular localization of c-
Jun and ERα were confirmed by the Western blot analysis. The results of WST-1 cell 
proliferation assays performed in c-Jun-overexpressing (MCF-7/c-Jun -Tet) cells were 
consistent with the known effects of c-Jun in ERα-positive cells to increase cell 
proliferation. Furthermore, we found that the overexpressed c-Jun resulted in reduced 
sensitivity of MCF7 cells to tamoxifen by performing clonogenic cell survival assays.  
To further analyze the cistromes of ERα and c-Jun, ChIP-seq was performed in the 
presence of vehicle, E2 or tamoxifen. 78% (24742 sites) of the E2-ERα bindings were 
identified as the tamoxifen-ERα binding regions. This is consistent with the previous study 
showing that the cistrome of E2 bound ERα is highly overlapped with that of tamoxifen 
bound ERα [334]. Similarity, 79% (19219 sites) of c-Jun binding regions under E2 
treatment overlapped with that in presence of tamoxifen. Comparing the cistrome data of 
ERα and c-Jun treated with E2 revealed that 51% (12394 sites) of the c-Jun cistrome 
overlaps with the ERα cistrome. On the other hand, either ERα or c-Jun had its unique 
cistrome comprised of 19391 and 11913 binding sites, respectively. Motif enrichment 
analysis showed that ERα/c-Jun shared binding sites were more enriched in binding motifs 
for AP-1 (34%) than for EREs (7%) supporting the importance of indirect ERα 
recruitment via tethering to AP-1. Interestingly, the FOXA1 motif was enriched in shared 
and unique binding sites of ERα or c-Jun. In addition, GATA3 motif was enriched in 
ERα/c-Jun shared and ERα unique binding sites but not in unique c-Jun binding sites. 
Furthermore, we found that c-Jun overexpression reprogramed ERα chromatin binding 
and modulated ERα-mediated gene regulation. We compared the ERα cistrome in c-Jun 
overexpressing cells (31785 binding sites) with ERα cistrome in parental MCF7 cells 
(18236 binding sites) reported in our previous study [335], which indicated that an overall 
increase in number of ERα binding sites and a robust redistribution of ERα binding to 
novel genomic loci upon c-Jun overexpression. Motif analysis of common binding sites 
shared by the novel gained ERα and c-Jun revealed the enrichment of AP-1 and FOXA1 
motifs rather than ERE motif. These results confirmed that estrogen/ERα-dependent 
signaling crosstalk with AP-1 is mediated through the tethering of ERα to DNA bound 
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AP-1. Moreover, the mechanisms of reprogramming ERα cistrome might be due to that 
AP-1 motif-containing regions are opened up by c-Jun, which can permit the interaction 
between ERα and c-Jun or ERα directly interact with EREs located within these regions. 
Thus, ERα availability for other genomic regions is reduced. In addition, we analyzed E2-
regulated transcriptome data (E2 vs. vehicle) in MCF-7/c-Jun -/+Tet and found that 
overexpression of c-Jun promoted de novo E2 regulation of genes, 290 E2-upregulated 
genes and 317 E2-downregulated genes only in cells with c-Jun-overexpression. 
Functional annotation of the 290 genes indicated that these genes are associated with cell 
division and mitotic nuclear division, which was consistent with our phenotypic studies. 
Except the role of overexpressed c-Jun in promoting tumor cell growth, the phenotypic 
studies also showed that c-Jun overexpression contributed to tamoxifen resistance. 
Therefore, we analyzed the c-Jun-induced transcriptomic profile and found that the 266 
upregulated genes significantly overlapped with the gene set upregulated in tamoxifen-
resistant MCF7 xenograft tumors [221]. Moreover, integrating data from cistrome, 
transcriptome and clinical data revealed that TGFBI is a target gene regulated by c-Jun-
reprogrammed ERα binding events associated with tamoxifen resistance. RT-qPCR and 
ChIP-qPCR results verified that TGFBI mRNA levels were increased upon c-Jun 
overexpression and both ERα and c-Jun bound to TGFBI gene. We further found that, in 
c-Jun-overexpressing breast cancer cells, the sensitivity of cells to tamoxifen is enhanced 
by knockdown of TGFBI. By performing immunofluorescence staining using tissue 
microarray, we also showed that the TGFBI expression level is higher in breast cancer 
than that in normal breast tissues. Similar finding has also been reported in other studies. 
For instance, it has been shown that TGFBI knockdown is associated with paclitacel 
resistance, a chemotherapeutic agent, in SKOC-3 ovarian cancer cells [251]. Some studies 
have shown that TGFβ pathway is related with chemotherapy resistance [336, 337]. 
In summary, a novel genome-wide footprint of ERα and AP-1 crosstalk is provided here 
and our data further suggest AP-1 and TGFBI signaling as investigational points of 
treatments in AP-1-overexpressing ERα-positive breast cancer. 
4.2   PAPER  II:  ENDOGENOUS  INTERACTION  PROFILING  IDENTIFIES  DDX5  
AS  AN  ONCOGENIC  COACTIVATOR  OF  TRANSCRIPTION  FACTOR  FRA-­
1  
Our previous study has shown that Fra-1 and c-Jun are highly expressed in TNBC [214], 
and AP-1 also plays a pivotal role in tumorigenesis. Understanding the interactions of 
protein-protein are fundamental to study the mechanism of AP-1 regulated gene 
expression. In this study, for the first time, we reported the interactome of Fra-1 in TNBC 
cells, which is important to detect novel coregulators of Fra-1.  
Firstly, we performed RIME experiments to explore chromatin-bound partners of Fra-1 in 
BT549 cells and identified 118 Fra-1 associated proteins significantly enriched compared 
with IgG IP control. These proteins are divided in 13 groups based on PANTHER protein 
class analysis. For example, 50 proteins are nucleic acid-binding proteins and 13 proteins 
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are transcription factors. These proteins were clustered to several groups according to 
biological functions, such as DNA repair proteins, mRNA processing/slicing proteins and 
proteins related with transcription regulations. These results are important to decipher 
molecular mechanisms of Fra-1 signaling in TNBC cells, as the composition of Fra-1 
protein complex can influence the Fra-1 regulation of downstream targets.  
Our study further showed that DDX5, belonging to the DEAD-box protein family of RNA 
helicases, was the most enriched Fra-1 interacting protein. Furthermore, we performed 
ChIP-seq for Fra-1 or DDX5 in BT549 cells, respectively, which is the first genome-wide 
map of Fra-1- and DDX5-binding sites in TNBC cells. Comparing the cistromes of Fra-1 
(30571 sites) and DDX5 (10836 sites) found that 62% of DDX5 binding sites overlapped 
with that of Fra-1. Genomic distribution analysis showed that Fra-1/DDX5-shared binding 
sites were more enriched at active promoter/5’ UTR regions compared with unique 
binding sites of Fra-1 or DDX5. Furthermore, motif enrichment analysis revealed that the 
most significantly enriched motif was consensus AP-1 motif in unique Fra-1 binding sites 
and Fra-1/DDX5-shared-binding sites, in agreement with direct DNA binding of AP-1 
protein to these regions. Regarding the unique DDX5-binding sites, CTCF motif was the 
most significant one, which is consistent with previous finding that DDX5 can form a 
complex with CTCF [338]. Above results provide evidences for a mechanism of DDX5 
recruitment to DNA through interaction with Fra-1.  
Moreover, based on the transcriptome data, we identified that DDX5 shares a substantial 
set of Fra-1 target genes and DDX5 in general has the same direction effects as Fra-1 on 
regulation of shared genes. These co-regulated genes are highly associated with TNBC 
cell growth. We already knew that deletion of Fra-1 could suppress the TNBC cell 
proliferation [214]. Therefore, to detect the DDX5 effects on Fra-1-driven cell growth, we 
performed WST-1 cell proliferation assay and clonogenic cell survival assay with specific 
or combined knockdown (KD) of Fra-1 or DDX5. The results demonstrated that DDX5 
promotes cell growth and enhances the effect of Fra-1 on cell growth. 
Furthermore, by performing AP-1 reporter luciferase assay, we found that AP-1-dependent 
transcriptional activation was enhanced when DDX5 was overexpressed, and knockdown 
of DDX5 reduced the activation. DDX5 had coactivating effect on endogenous AP-1 
regulated genes containing shared Fra-1/DDX5 binding sites. In addition, the ChIP-qPCR 
results showed that Fra-1 KD decreased the recruitment of DDX5 to the co-occupied 
regions in co-regulated genes. However, DDX5 KD did not influence Fra-1 enrichment at 
the same regions. Previous studies have shown that DDX5 can act as a transcriptional 
coactivator for several transcription factors, such as AR, ER and P53, etc [299, 301]. 
Totally, above evidences support that DDX5 acts as a coactivator of Fra-1, and Fra-1 is 
essential for DDX5 recruitment to the common genomic targets.  
The further integration of cistrome and transcriptome data showed that DDX5 direct target 
genes interacted with chromatin, including 220 downregulated and 260 upregulated genes 
by DDX5 KD containing DDX5 binding sites. Gene ontology analysis suggested that 
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DDX5 direct target genes are involved in functions related with tumor characteristics, 
including “regulation of cell migration”, “regulation of cell proliferation” and “regulation 
of cell adhesion”. Additionally, the results of immunoprecipitation staining showed the 
expression level of DDX5 protein is upregulated in basal like-type breast cancer, 
compared with non-basal like tumors. Clinically, DDX5-regulated gene expression set in 
breast cancer predicts clinical outcomes. Therefore, high expression of DDX5 is related 
with the more aggressive subtypes. It is highly likely that DDX5 promotes Fra-1-
dependent breast cancer cell growth through enhancing the transcriptional activity of AP-1. 
Together, we elucidated the first interactome data of Fra-1 in TNBC cell. DDX5 acts as a 
transcriptional coregulator of AP-1-mediated gene expression and promotes cell growth of 
TNBC. Thus, these findings suggest that strategies to interfere with this function of DDX5 
may be of therapeutic benefit. 
4.3   PAPER  III:  ERa  AND  ERb  EXERT  DIFFERENTIAL  REGULATION  OF  GENE  
EXPRESSION  IN  MCF7  CELLS  
In previous in vitro studies, the most often used breast cancer cell models are co-
expressing endogenous ERα and recombinant ERβ, which is not sufficient to provide 
comprehensive information on the specific roles of ERβ homodimers in ERα-positive cells. 
Therefore, in this study, we generated a novel breast cancer cell model, the only ERβ-
expressing MCF7 cell line, to further complement the understanding of the unique 
functions of ERα or ERβ in ERα-positive breast cancer cells. 
First, to generate the only ERβ-expressing MCF7 cell line, we used CRISPR/Cas9 system 
to knock out ERα in the Tet-Off-inducible ERβ MCF7 cell line. The reasons why we 
choose the Tet-Off-inducible ERβ MCF7 cell line are as follows, first, the cell line was 
generated and available in our lab [339]; second, this cell line contains Tet-off system, 
which can express endogenous ERα and inducible ERβ in the absence of Tet. DNA 
sequencing showed that the transfected sgRNA that targeted on exon 1 of ESR1 gene 
caused frameshifting insertions to stop the expression of ERα. In line with this, the cell 
model was also validated by the Western blot analysis. Therefore, in the absence of Tet, 
the cell model only expresses ERβ without ERα expression.  
Furthermore, we selected four known estrogen-responsive genes, including PKIB, PS2, 
IL20 and GREB1, to examine the role of ERβ in regulation of gene expression. E2 
stimulation upregulated the gene expression of PS2, GREB1 and PKIB while 
downregulated IL20 expression mediated through ERβ. This confirmed that ERβ was 
functional to regulate these genes upon the E2 stimulation in the absence of ERα, which 
supports that the transactivation of ERβ homodimer is ligand-dependent. 
Since the role of ERβ on cell proliferation is still inconsistent to date, we performed WST-
1 assay to assess the proliferation phenotype in only ERα- or ERβ-expressing MCF7 cells. 
We found that only ERβ expression reduced the cell growth rate compared with only ERα-
expressing MCF7 cells cultured in full-serum medium. In addition, we found that only 
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ERβ-expressing MCF7 cells displayed a significant reduction in cell proliferation in 
response to E2 compared with vehicle. Conversely, only ERα-expressing MCF7 cells 
displayed an increased cell proliferation upon E2 treatment. Therefore, in our study, ERα 
and ERβ have opposing roles on E2-dependent cell proliferation. 
Moreover, we performed RNA-Seq analysis in hormone deprived only ERα- or ERβ-
expressing MCF7 cells with E2 stimulation. The data revealed that 1359 and 1567 genes 
was regulated by only ERα or ERβ in response to E2 (|FC|>2, FDR<0.05), respectively. 
We also found that 31% of E2-upregulated genes in only ERβ-expressing MCF7 cells 
overlapped with that in only ERα-expressing MCF7 cells, and 45% of E2-downregulated 
genes modulated by ERβ overlapped with that in only ERα. These results indicated that 
ERβ can modulate specific gene expression profile different from that of ERα. In addition, 
the results of functional enrichment analysis for two ER isoform-specific E2-upregulated 
genes showed that either ERα or ERβ uniquely modulated genes have various molecular 
and cellular functions.  The results of GO analysis further indicated that two ER isoforms 
function in opposite direction to regulate cell proliferation. The ERα-specifically 
upregulated genes are enriched in the biological process “positive regulation of cell 
proliferation”, consistent with the known effect of E2 in ERα-positive cells. While the 
gene set that specifically upregulated by ERβ are significantly involved in the biological 
process “negative regulation of cell proliferation”, in line with the observed phenotypic 
differences. 
In conclusion, the significance of this study is the generation of novel only ERβ-
expressing MCF7 cell model. This cell model is foundational resource for us to detect the 
specific roles of ERα and ERβ in ERα-positive breast cancer cells. Our study also suggests 
that two ERs isoforms have opposite effects on cell proliferation through regulating 
distinct sets of target genes in response to E2. 
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5   CONCLUDING  REMARKS  AND  PERSPRECTIVES  
5.1   AP-­1  IN  ERa-­POSITIVE  BREAST  CANCER  
A critical mechanism of ER signaling, tethering mechanism, has been proposed, in which 
ligand-activated ERα indirectly interacts with DNA via other transcription factors, such as 
AP-1. In this thesis, we investigated the genome-wide assessment of c-Jun, a potent member 
of AP-1 family, and ERα cistrome and transcriptome in ERα-positive breast cancer cells, 
which demonstrate the co-localization of ERα and c-Jun binding regions at genome-wide 
level and suggests that ERα tethering to AP-1 is a global mechanism for gene transcription 
regulated by ERα. In addition, the results showed that the sensitivity of ERα-positive breast 
cancer cells to tamoxifen therapy is reduced by the overexpression of c-Jun. This is consistent 
with earlier findings that enhanced AP-1 transcriptional activity is associated with endocrine 
therapy resistance [209, 221]. Moreover, it is shown that TGFBI is associated with poor 
outcomes of ERα-positive breast cancer patients receiving endocrine therapy and a potential 
gene that may cause tamoxifen resistance through the crosstalk of ERα and AP-1. 
In summary, this thesis highlights a role of AP-1 and ERα crosstalk through regulation of 
TGFBI expression as a potential contributor of endocrine resistance in ERα-positive breast 
tumors. On the other hand, it has previously been indicated that TGFBI can function as a 
chemo-sensitizer or a risk of chemo-resistance in various cancers [227, 228]. Therefore, a 
more comprehensive understanding of TGFBI signaling mechanism will be essential to 
identify novel strategies to overcome endocrine therapy resistance. 
5.2   AP-­1  IN  TNBC  
Fra-1, a member of AP-1 transcription factors, has been shown to be overexpressed in TNBC 
and associated with poor prognosis [214]. The downstream gene regulation of Fra-1 can be 
influenced by associated coregulators and thus the alterations in the composition of Fra-1 
protein complex may have direct clinical implications. In this thesis, the first interactome data 
of Fra-1 in TNBC cells is reported, highlighting that DDX5 is the most enriched interacting 
protein of Fra-1. Furthermore, it is shown that DDX5 has a role of transcriptional coactivator 
for Fra-1, which is able to enhance Fra-1-dependent TNBC cell proliferation through 
increasing the transcriptional activity of Fra-1. 
As we know, currently, there is still no effective target therapy for TNBC. This thesis also 
shows that DDX5 expression level is higher expressing in triple-negative basal-like tumors 
than that in non-basal-like ones. In addition, the direct target gene set of DDX5 can predict 
poor clinical outcome of breast cancer patients. Moreover, interfering with the DDX5 
coregulatory effect for Fra-1 could alter AP-1 mediated gene expression involved in tumor 
progression. Therefore, DDX5 might be a candidate for targeting therapy in TNBC patients.   
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5.3   ERb  IN  ERa-­POSITIVE  BREAST  CANCER  
In breast cancer, the function of ERα is more clearly defined compared with ERβ. In this 
thesis, we generated a novel cell model, only ERβ-expressing MCF7 cell line, using 
CRISPR/Cas9 system to knock out ERα. This cell model is better to study the functions of 
ERβ homodimers in ERα-positive breast cancer cells, compared with most previously used 
cell models which contain co-expression of ERα and ERβ. Therefore, this novel cell model is 
an important resource to further complement the understanding of the roles of two different 
ER isoforms in ERα-positive breast cancer cells. It also provides the evidence that two ERs 
have opposite effects on E2-dependent cell proliferation by regulating distinct sets of target 
genes in respond to E2. The different pattern of gene expression profile uniquely regulated by 
ERα or ERβ is fundamental. It is essential to further study the mechanism of two different ER 
isoform signaling, especially the target genes and signaling pathway associated with tumor 
cell growth, to identify the novel strategies for breast cancer therapy.    
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